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A Baker’s Dozen of Top Antimicrobial Stewardship
Intervention Publications in 2019
Kayla R. Stover,1, Elias B. Chahine,2, David Cluck,3, Sarah Green,4 Daniel B. Chastain,5, Darrell Childress,6 Carmen Faulkner-Fennell,7,8 Katherine
Lusardi,9 Edoabasi U. McGee,10, Michelle Turner,11 P. Brandon Bookstaver,12, and Christopher M. Bland13

Staying current on literature related to antimicrobial stewardship can be challenging given the ever-increasing number of published
articles. The Southeastern Research Group Endeavor (SERGE-45) identified antimicrobial stewardship–related peer-reviewed literature that detailed an actionable intervention for 2019. The top 13 publications were selected using a modified Delphi technique.
These manuscripts were reviewed to highlight the actionable intervention used by antimicrobial stewardship programs to provide
key stewardship literature for teaching and training and to identify potential intervention opportunities within one’s institution.
Keywords:
antibiotics; antimicrobial stewardship; infectious diseases; metrics; resistance.
Antimicrobial stewards and infectious diseases (ID) clinicians
experienced important advances throughout 2019. Included
among the new antimicrobial approvals by the Food and Drug
Administration were new agents to combat multidrug-resistant
(MDR) gram-negative infections (cefiderocol and imipenem/
cilastatin/relebactam), community-acquired pneumonia with
a novel mechanism of action (lefamulin), and MDR tuberculosis (pretomanid) [1]. While the advent of new agents brings
hope in managing difficult-to-treat infections, positioning
these new drugs on formularies and in treatment decisions remains a constant challenge for stewardship teams. Additionally,
several pharmaceutical companies continue to struggle with
or abandon the antimicrobial market as sales of new agents
flounder, which calls into question the future of novel antimicrobial approvals [2, 3].
The year brought mixed news regarding antimicrobial resistance rates. As reported by the Centers for Disease
Control and Prevention (CDC) in the 2019 edition of the
Antibiotic Resistance Threats report, proportions of traditional
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hospital-acquired infections such as MDR Pseudomonas
aeruginosa and Acinetobacter baumannii declined, perhaps owing to the impact of acute care stewardship teams
meeting CDC core elements [4–6]. In contrast, the proportion of extended-spectrum beta-lactamase (ESBL)–producing
Escherichia coli increased, emphasizing the need for focused
stewardship efforts outside the hospital walls [4]. Reducing unnecessary antimicrobial prescriptions and overall antimicrobial
utilization remain valued metrics and pillars for successful antimicrobial stewardship teams to combat the untoward effects of
antimicrobials [7].
The body of literature continues to grow, offering new ideas
and strategies along with supporting data reinforcing traditional interventions for antimicrobial stewardship teams. Since
2016, members of the Southeastern Research Group Endeavor
(SERGE-45), an interprofessional research network primarily
composed of expert pharmacist stewards in the Southeastern
United States, has systematically compiled and reviewed publications involving an antimicrobial stewardship intervention
annually [8–11]. The top 13 selected articles from 2019 are detailed herein and briefly reviewed in Table 1 [12–24].
METHODS

Using a modified Delphi technique (detailed previously), members of the SERGE-45 network identified antimicrobial stewardship publications from 2019 considered to be significant
using the following inclusion criteria: (1) published in 2019, including electronic, “early-release” publications, and (2) included
an actionable intervention [25]. An actionable intervention
was defined as a stewardship strategy that was implemented in
Top Stewardship Interventions 2019 • ofid • 1
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Table 1.

Summary of Top 13 Antimicrobial Stewardship Intervention Papers, 2019

Study Citation Study Design

Intervention Summary

Primary and Key Secondary Outcomes

Brotherton
Single-center, retrospective quasiet al. J
experimental study in a large acaAntimicrob
demic medical center comparing
Chemother adherence to an institutional SAB
2020;
management bundle
75:1054–60
[12].

Upon isolating Staphylococcus aureus
from blood cultures, clinical decision support software triggered an
automated, hard-stop alert in the
electronic health record prompting
providers to use a 6-component
SAB bundle, which consisted of (1)
infectious diseases consultation,
(2) source control, (3) echocardiogram, (4) repeat blood cultures, (5)
antimicrobial therapy, and (6) appropriate duration.

Primary outcome:
-Adherence to all 6 components of SAB bundle: 29.7% vs 56.9%;
P < .001
Secondary outcomes:
-ID consult within 5 days of positive culture: 76.6% vs 88.8%;
P = .021
-Source control: 54.1% vs 79.3%; P < .001
-Repeat blood cultures within 72 hours of initial positive: 98.2%
vs 100%; P = .238
-Echocardiogram: 76.6% vs 83.6%; P = .244
-Antimicrobial therapy: 94.6% vs 96.6%; P = .532
-Appropriate duration: 80.2% vs 83.6%; P = .605
-90-day readmission due to SAB complications: 14.3% vs 8.3%;
P = .256

Erickson
Retrospective, single-center cohort
Antimicrobial stewardship bundle
et al. Open study comparing a pre-antimicrobial in conjunction with rapid diagForum
stewardship period with a
nostic testing for uncomplicated
Infect
postantimicrobial stewardship
gram-negative bacteremia: proDis 2019;
period
moting IV-to-PO switches, 7-day
6:XXX–XX
antibiotic durations, advising against
[13].
repeat blood cultures. This is compared with a pre-antimicrobial
stewardship period with only rapid
diagnostic testing available.

Primary outcome:

Peñalva et al. Quasi-experimental, interrupted time- Education that focused on 5 aspects:
Lancet
series study across 214 primary
1. Central and local dissemination of
Infect
health centers in 4 primary health
program information
Dis 2019;
care districts
2. Open online courses focused on
20:199–207
appropriate antibiotics for common
[14].
infections

Primary outcomes:

-Shorter median treatment duration in the ASP bundle group (10
vs 14 days; P < .001)
Secondary outcomes:
-Earlier switch to PO therapy (day 4 vs day 5; P = .046)
-Lower 30-day all-cause readmission (23.3% vs 39.2%; P = .047)
-Lower incidence of repeat blood cultures (44.2% vs 66.7%;
P = .01)
-No difference in 30-day mortality (0 vs 2.3%; P = .27)
-Inappropriate antibiotic prescribing had an annual change of
3.2% (36.5% in 2014 to 26.9% in 2017; P = .001)
Incidence density of ESBL-producing E coli in urine cultures: RR
–65.6% 4 years after start of program:

3. Regular in-person clinical protocol
updates

-Pre-intervention (2012–2013) increase: 0.004 cases per 1000
inhabitants; P < .0001

4. Educational interviews

-Intervention (2014–2017) decrease: –0.006 cases per 1000 inhabitants; P < .0001

5. Quarterly reports with analysis
Christensen Retrospective, single-center, quasiet al. Inexperimental
fect Control Hosp
Epidemiol
2019;
40:269–75
[15].

A C. difficile NAAT ASP preauthorization and chart review was
initiated in October 2016. A preimplementation period of January
2014 to September 2016 was compared with a postimplementation
period of October 2016 to April
2018. The ASP pharmacist prospectively reviewed all weekday
C. difficile NAAT orders and
provided recommendations for
canceling those that did not meet
testing criteria.

Primary outcome: pre-implementation vs postimplementation

Seddon et al. Retrospective, multicenter cohort
Clin Infect
study
Dis 2019;
69:414–20
[16].

Risk of CDI was examined in adults
hospitalized for >48 hours for the
treatment of Enterobacterales
bloodstream infections.

Primary outcome:

-Mean monthly NAAT, 15.4 vs 12.4; P = .018
Secondary outcomes: pre-implementation vs postimplementation
-HO-CDI-IR, 8.5 vs 6.4 per 10 000 patient days; P = .0036
-SIR, 0.97 vs 0.78; P = .015
-Mean vancomycin consumption,10.8 vs 10.7 DOT/1000 DP;
P = .91

-Higher incidence of CDI in patients who received >48 hours of
APBL: 7.0% (95% CI, 4.2% to 9.8%) vs 1.8% (95% CI, 0.4%
to 3.2%) in patients who received ≤48 hours of APBL; log-rank
P = .002
Secondary outcomes:
- Receipt of >48 hours of APBL was associated with an HR of
developing CDI of 3.56 (95% CI, 1.48 to 9.92); P = .004
-End-stage renal disease was associated with an HR of developing CDI of 4.27 (95% CI, 1.89 to 9.11); P = .001
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-30-day all-cause mortality: 12.6% vs 6%; P = .110

Table 1. Continued
Study Citation Study Design

Intervention Summary

Depuy et al. Retrospective, single-center cohort
Medication reconciliation and daily
Open
study evaluating impact of an ARV
review of ARV medications
Forum
stewardship team on identification
throughout inpatient admission by
Infect
and correction of ARV medication
an interdisciplinary pharmacist–phyDis 2019;
errors
sician ARV stewardship team. In6:XXX–XX
cluded contact with outpatient HIV
[17].
providers for regimen confirmation
and standardized communication
with the primary team via documentation in the EHR.

Primary and Key Secondary Outcomes
Primary outcome:
-336 interventions made by ARV stewardship team over
12-month period; drug interaction (45.2%), incorrect regimen
(17.9%), and OI prophylaxis (10.1%) errors occurred most frequently
Secondary outcomes:
-43.2% of hospitalizations with ARV orders required at least 1
intervention
-96.4% intervention acceptance rate
-$263 428 estimated associated cost savings

Langford et al.Pre/post design over a 4-year
Pre-intervention: low-intensity phase
Infect Conperiod examining impact of a
24 months before the intervention
trol Hosp
high-intensity, interdisciplinary,
-ASP pharmacists provided PAF to
Epidemiol
round-based PAF compared with a
prescribers on 5 internal medicine
2019;
low-intensity PAF on antimicrobial
units; focus on patients receiving
40:1344–47 use measured in DDD per 1000
targeted antibiotics
[18].
PD on internal medicine wards in a
-1-on-1 recommendation to the
400-bed community hospital
internal medicine physician performed for each patient requiring
intervention

Primary outcomes:
-Low-intensity phase antimicrobial use: 483 DDD/1000PD vs 442
DDD/1000PD in high intensity (difference, –42; 95% CI, –74
to –9)
-Adjusted analysis to account for seasonality (difference, –93
DDD/1000PD; 95% CI, –169 to –20)

Postintervention: high-intensity phase
24 months

Secondary outcomes:

-Structured, twice-weekly ASP rounds

Adjusted analysis to account for seasonality: postintervention
period:

-Interdisciplinary team (ward pharma-Months 1–12, 483.3 DDD/1000PD in low-intensity group vs
cist, internal medicine physician,
458.3 DDD/1000PD in high-intensity group (difference, –75.3;
ASP pharmacist, and ASP physician)
95% CI, –145.9 to –5.9)
rounded for 30 minutes per unit
-Internal medicine physician made
final decision after PAF recommendation

-Months 13–24 in low-intensity group 483.3 DDD/1000PD vs
high-intensity group 415.5 DDD/1000PD (difference, –121.5;
95% CI, –217 to –28.3)
Targeted antibiotics:
-153.1 DDD/1000PD in low-intensity vs high-intensity group 141
DDD/1000 PD (difference, –50.1; 95% CI, –71.7 to –28)
-No changes in clinical outcomes of CDI, readmission rate, or
mortality after the switch to high-intensity PAF

Bolten et al. Retrospective study evaluating antiAm J
biotic usage comparing traditional
Health Syst ASP PAF with implementation of
Pharm
an ADAP
2019;
76:S85–90
[19].

Shively et al. Multicenter, quasi-experimental,
Clin Infect
pre- and postintervention study
Dis 2020;
71:539–45
[20].

Implemented an automatic antibiotic
discontinuation policy of antibiotics
authorizing ASP team to stop
antibiotics therapy in cases with
inappropriate duplicate antimicrobial coverage (atypical, anaerobic,
dual-β-lactam without documented
rational) or excess duration of
therapy in specified disease states/
or antibiotics >48 hours and no
documented infection

Primary outcome:

Review of patients on broad-spectrum
antimicrobials and those admitted
with lower respiratory tract infections and skin and soft tissue infections by remote ID physicians and
local pharmacists

Primary outcomes:

-Mean total antibiotic days per patient (7.6 days vs 6.6 days;
P < .05)
Secondary outcome:
-Mean excess days of antibiotics (2.3 days vs 1.5 day; P < .05)
-Patients prescribed antibiotics at discharge (18.5% vs 8%;
P < .05)
-30-day readmission (12.3% vs 14.2%; NS)
-CDI (1 vs 2 cases; NS)
-Multidrug-resistant infection (4.3% vs 2.5%; NS)
-A total of 1419 recommendations were made, of which 1262
(88.9%) were accepted
-Decrease in tier 1 antimicrobial use (DOT/1000 PD): 10.6 during
the intervention period vs 16.3 in historical control; P = .04
-Decrease in tier 2 antimicrobial use (DOT/1000 PD): 248.2 during
the intervention period vs 325.9 in historical control; P < .001
-Numerical decrease in total antimicrobial use (DOT/1000 PD):
820.7 during the intervention period vs 777.1 in historical control; P = .18
-Increase in ID consultations/1000 PD: 21.5 during the intervention period vs 15.4 in historical control; P = .001
-Estimated annual cost-savings: $104 087.34 on tier 1 antimicrobials
and $56 239.05 on tier 2 antimicrobials vs increase of $17 696.55
on nontiered antimicrobials (difference, $142 629.83)
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-Multivariable analysis identified multitablet inpatient regimen
(P = .009), ICU admission (P = .01), surgical care (P = .02),
days reviewed (P = .02), and noninstitutional HIV provider
(P = .07) as risk factors for ARV medication errors

Table 1. Continued
Study Citation Study Design

Intervention Summary

Anderson
Multicenter, historically controlled,
Modified PA by pharmacists
et al. JAMA prospective, nonrandomized clinical and PPR by the stewardship
Netw
trial with crossover design
team targeting vancomycin,
Open 2019;
piperacillin-tazobactam, and the
2:e199369
antipseudomonal carbapenems on
[21].
formulary

Primary and Key Secondary Outcomes
Primary outcomes:
-Intervention approval processes took a median of 95 days
-Pharmacists performed 1456 interventions (median per hospital,
350) during PA and 1236 interventions (median per hospital,
298) during PPR
-Recommendations were accepted by clinicians in 79.2% of
cases during PA and 69.0% during PPR
-More study antibiotics were determined to be inappropriate
during PPR: 41.0% during PPR vs 20.4% during PA; P < .001
-Pharmacists recommended de-escalation more during PPR:
29.1% during PPR vs 13.0% during PA; P < .001
-Pharmacists recommended dose change more during PA: 15.9%
during PA vs 9.6% during PPR; P < .001

Secondary outcomes:
-No decrease in antibiotic use (DOT/1000 PD) during PA: 931.0 vs
926.6 during matched historical control (difference, 4.4; 95%
CI, –55.8 to 64.7)
-Decrease in antibiotic use (DOT/1000 PD) during PPR: 925.2 vs
965.3 during matched historical control (difference, –40.1; 95%
CI, –71.7 to –8.6)
-Same median length of hospitalization per admission for PA,
PPR, matched historical control
Gross et al. Implementation of antimicrobial
Multimodal intervention consisting of
Open
stewardship in an academic dental
standardizing antimicrobial therapy
Forum
practice using the CDC Core Elemfor acute dentoalveolar conditions,
Infect
ents of Outpatient Antimicrobial
educational interventions, and
Dis 2019;
Stewardship
patient-facing educational posters
6:XXX–XX
focusing on the necessity of anti[22].
biotics and potential harms

Primary outcome:

Webb et al. Retrospective quasi-experimental
Utilized monthly antibiotic cycling with
Clin Infect
pre- and postimplementation of 2
either piperacillin-tazobactam or
Dis 2019;
antimicrobial stewardship intervencefepime (with or without metroni68:498–500 tions in an inpatient hematological
dazole) and a previously described
[23].
malignancy treatment unit
clinical prediction tool to guide empiric VRE therapy when managing
febrile neutropenia

Primary outcomes:

-72.9% decrease in antibiotic prescribing rate per urgent care visit
(pre-intervention urgent care prescribing rate, 8.5% [24/283];
postintervention, 2.3% [8/352]; P < .001)

-Carbapenem use decreased by 230 DOT/1000 PD (95% CI, −290
to −180; P < .001)
-Unadjusted antipseudomonal carbapenem use decreased after
intervention (396.5 vs 123.4 DOT/1000 PD; P < .001)
-Daptomycin prescribing (−160 DOT/1000 PD; 95% CI, −200 to
−120; P < .001)
-VRE clinical prediction score (−30 DOT/1000 PD; 95% CI, −50 to 0; P = .08)
Secondary outcomes:
-VRE colonization (OR, 0.64; 95% CI, 0.51 to 0.81; P < .001)
and infection decreased after intervention (2.38 vs 1.08 infections/1000 PD; P = .006)
-Infection due to ESBL-producing Enterobacteriaceae increased
(0.14 to 0.81/1000 PD; P = .01) postintervention
-No impact on inpatient mortality (OR, 0.91; 95% CI, 0.6 to 1.5; P = .72)

Graber et al. Pre/post quasi-experimental study
Development of interactive graphic tools
Clin Infect
evaluating impact of novel antifor dissemination of in-depth facilityDis 2020;
microbial use visualization tools on
level antimicrobial usage data to
71:1168–76 antimicrobial usage at 8 VA inpatient facility stewards. The tools were op[24].
facilities
timized based on collaborative feedback from the 8 volunteer facilities
and ultimately provided dashboards
that could be filtered by antimicrobial use decision point, antimicrobial
agent type, unit, disease state, or
SAAR category and compared with
similar or all VA facilities. Change
in antimicrobial use was assessed
pre-intervention (January 2014–January 2016) and postintervention (July
2016–January 2018).

Average change in DOT/1000 DP at intervention vs nonintervention sites
Primary outcome:
-Total inpatient antimicrobial use: –2.1% (95% CI, –5.7% to 1.6%;
P = .2529) vs +2.5% (95% CI, 0.8% to 4.1%; P = .0026); absolute difference, 4.6% (P = .025)
Secondary outcomes:
-Total inpatient use of anti-MRSA agents: –11.3% (95% CI,
–16.0% to –6.3%; P < .0001) vs –6.6% (95% CI, –9.1% to
–3.9%; P < .0001); absolute difference, 4.7% (P = .092)
-Total inpatient use of antipseudomonal agents: –3.4% (95% CI,
–8.2% to 1.7%; P = .185) vs +3.6% (95% CI, 0.8% to 6.5%;
P = .011); absolute difference, 7.0% (P = .018)

Abbreviations: ADAP, automatic discontinuation of antibiotics policy; APBL, antipseudomonal β-lactam; ARV, antiretroviral; ASP, antimicrobial stewardship programs; CDC, Centers for Disease Control
and Prevention; CDI, Clostridioides difficile infection; DDD, defined daily dose; DOT, days of therapy; DP, days present; EHR, electronic health record; HO, hospital-onset; HR, hazard ratio; ICU, intensive
care unit; ID, infectious diseases; IQR, interquartile range; IR, incident rate; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; NAAT, nucleic acid amplification tests; NS, nonsignificant;
OI, opportunistic infection; OR, odds ratio; PA, preauthorization; PAF, prospective audit and feedback; PD, patient-days; PO, per oral; PPR, postprescription audit and review; RR, relative reduction; SAAR,
standardized antimicrobial administration ratios; SAB, Staphylococcus aureus bacteremia; SIR, standardized infection ratio; VA, Veterans Affairs; VRE, vancomycin-resistant Enterococcus.
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-The median time dedicated to the stewardship interventions
varied by hospital (range of median hours per week, 5–19)

RESULTS
Automated Stewardship
Bloodstream Infection

Intervention

for

Staphylococcus

aureus

Management of Staphylococcus aureus (SA) bloodstream infection (BSI) remains challenging, with mortality rates around
20% [27]. Furthermore, adherence to evidence-based recommendations for managing SABSI continues to be suboptimal.
Brotherton and colleagues conducted a single-center, retrospective quasi-experimental study to evaluate rates of adherence
and clinical outcomes after implementing an SABSI management bundle [12]. The intervention used an automatic, hardstop alert in the electronic health record directing providers to
use an electronic order set after detection of SABSI. Providers
were required to utilize the order set or provide a reason for
dismissing the alert. In addition, brief educational sessions regarding guideline location and bundle elements were provided
before implementation.
In total, 227 patients were included (111 in the preintervention group compared with 116 in the postintervention
group), of which almost all were complicated SABSI (97.3%
vs 92.2%, respectively; P = .136). Adherence to all components of the bundle occurred significantly more often in the
postintervention group (Table 1). In the postintervention
group, the median time to repeat blood cultures and sterilization of blood cultures was significantly shorter, and the median time from SABSI identification to alert activation was 0.5
hours. Despite alert activation occurring in 95.7% of cases in
the postintervention group, the order set was utilized in only

57.8%. No differences in hospital length of stay, 30-day mortality, or 90-day readmission for SABSI complications were observed between groups.
As opposed to other SABSI management bundles requiring
prospective audit with intervention and feedback, this study reinforces the possibility of utilizing an automated antimicrobial
stewardship intervention to improve management. Although
high rates of adherence to individual components of the bundle
were observed, adherence to all components remained low.
Impact of a Stewardship Bundle on Gram-Negative Bacteremia

The literature for gram-negative BSI has significantly changed
treatment recommendations by supporting shorter treatment durations [28], early switch to oral antibiotics [29], and
demonstrating lack of benefit of repeat blood cultures [30].
Using an approach that is well described in gram-positive infections, Erickson and colleagues conducted a single-center,
retrospective cohort evaluation of an antimicrobial stewardship
bundle coupled with rapid diagnostic tests (RDTs) for uncomplicated gram-negative bacteremia [13]. The prestewardship
group did not have an active stewardship intervention, whereas
the poststewardship group had 0.5 full-time equivalent (FTE)
physicians and 1 FTE pharmacist to implement the bundle,
which included intravenous-to-oral (IV-to-PO) antibiotic
switches, 7-day antibiotic durations, and avoidance of repeat
blood cultures. Patients with uncomplicated gram-negative
bacteremia (monomicrobial, with source control, and no immunosuppression or indications for longer duration of therapy)
managed with active therapy within the first 24 hours were eligible for inclusion.
The main infection source was the urinary tract, and the most
common organism was E. coli. The poststewardship group had a
shorter median duration of antibiotic therapy, and patients were
switched to oral antibiotics sooner, had fewer repeat cultures
obtained, and had a lower 30-day readmission rate. Mortality
and bacteremia recurrence were similar between the groups.
This study demonstrated the efficacy of an antimicrobial stewardship bundled approach coupled with rapid diagnostic testing
for management of uncomplicated gram-negative bacteremia
and further supports the safety of shorter durations of antibiotics in these patients.
Impact of Education in Primary Care on ESBL Escherichia coli in the
Community

Education alone is noted to be a low-effectiveness stewardship
strategy, unless it is combined with real-time intervention(s)
[31]. Peñalva and colleagues evaluated the impact of structured
and consistent educational efforts on rates of ESBL E. coli in
Spain [14]. The study spanned from January 2012 to December
2017 (pre-intervention 2012–2013, intervention 2014–2017)
and included 5 interventions (shown in Table 1). The educational interview was the core strategy. A patient who received

Top Stewardship Interventions 2019 • ofid • 5

Downloaded from https://academic.oup.com/ofid/article/7/10/ofaa402/5902822 by guest on 25 May 2022

practice and resulted in measurable outcomes. Clinical practice guidelines, official statements, review articles, and articles
without an actionable intervention were excluded.
A PubMed search using “antimicrobial stewardship” for
2019 revealed 1293 potential publications. P.B.B. screened abstracts to ensure that all relevant articles were considered. In
addition, 79 author-identified publications (most duplicated
from the literature search) were submitted for potential inclusion. C.M.B., K.R.S., and P.B.B. screened these to ensure that
articles met inclusion criteria. During the first round of reviews, a total of 60 articles were distributed to the SERGE-45
network (65 members) for ranking using SurveyMonkey based
on contribution and/or application to antimicrobial stewardship programs (ASPs); 21 participants (32%) ranked their top
13 based on clinical judgment [26]. During the second round,
12 authors (100%) ranked their top 13 based on clinical judgment. Finally, in a teleconference C.M.B., K.R.S., and P.B.B. reviewed the group ranks and established final consensus on the
top 13 articles based on number of votes received for each article, described herein. Figure 1 is a flowchart of the database
and article selection process, and Table 1 is a summary of the
selected articles.

Articles retrieved from a PubMed
search using the term
“antimicrobial stewardship”
limited to 2019 publication year
N = 1293

Articles on antimicrobial
stewardship submitted by
members of SERGE-45
N = 79

Top ranked articles by members of SERGE-45
selected for review
N = 13

Figure 1.

Flowchart of the database search and article selection process.

antibiotics was randomly selected, then the diagnosis and antibiotic course were reviewed with the prescriber and determined
to be appropriate or inappropriate. Prescribers received an average of 5 interviews annually. Antibiotic consumption and
ESBL incidence were assessed quarterly.
The study included 1 937 512 individuals seen by 1387 prescribers, who underwent 24 150 educational interviews.
Each year of the intervention period saw an 11% increase in
interviews conducted and a 3.2% decrease in inappropriate
prescribing (P = .001). The most common causes for an “inappropriate” prescription were agent selection (36.9%) and duration (34.5%). Decreases in use were identified for ciprofloxacin
and cefuroxime, but not for third-generation cephalosporins.
No changes were noted for levofloxacin and amoxicillinclavulanate, and increases were identified for amoxicillin and
fosfomycin.
Susceptibilities were performed on 67 428 E. coli isolates
during the 6 years, with a significant change in the rate correlating to the start of the intervention. Pre-intervention, the proportion of ESBL-producing E. coli was 7.1%, and by the end of
the intervention period it was 5.5% (P = .0001).
This study was supported and funded by the Spanish government, marking high commitment within the European Union
for antimicrobial stewardship. This study showed that consistent educational contact impacts prescribing and decreases
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resistance, especially in the primary care environment where
the majority of antibiotic prescribing occurs. Additionally, it
took an important step toward linking decreased antibiotic consumption to a meaningful outcome.
Diagnostic Stewardship and Clostridioides difficile Testing

RDTs are important tools for ASPs. The 2017 Infectious Diseases
Society of America (IDSA) and Society for Healthcare and
Epidemiology of America guidelines for Clostridioides difficile
infections (CDIs) have specific recommendations for the use of
nucleic acid amplification tests (NAATs) [32]. These include the
use of either a multistep test involving NAAT, glutamate dehydrogenase (GDH), and/or toxins with NAAT, or NAAT alone
with established testing criteria. However, inappropriate use of
C. difficile RDTs may lead to false-positive results and the treatment of asymptomatic patients.
Christensen and colleagues performed a quasi-experimental
retrospective, single-center study evaluating ASP-led education
and prior authorization on C. difficile NAATs [15]. The study
had a pre-intervention period from January 2014 to September
2016 and a postintervention period from October 2016 to April
2018. During the postintervention period, an ASP pharmacist
reviewed all weekday NAATs ordered on hospital day ≥4. Of
note, this study used NAAT testing alone, not multistep testing.
The ASP pharmacist evaluated clinical signs and symptoms
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Articles that met the inclusion criteria of actionable
antimicrobial stewardship intervention and
distributed for ranking
N = 60

Early De-escalation of Antibiotic Therapy and Risk of Clostridioides
difficile Infection

The association between use of broad-spectrum antibiotics and
risk of CDI is well established [33]. Seddon and colleagues sought
to determine the impact of early de-escalation of antipseudomonal
β-lactam (APBL) antibiotics on the risk of CDI within 90 days in
patients hospitalized for the treatment of Enterobacterales BSI
in South Carolina [16]. Patients 18 years and older who had a
first episode of monomicrobial BSI due to Enterobacterales from
January 1, 2011, to June 30, 2015, who were identified through
microbiology laboratory databases and who had a full 48-hour
window for de-escalation of antibiotics were included. Patients
who had a CDI within 1 year of BSI and those with concurrent
CDI and BSI were excluded. A total of 808 patients were included
(414 received >48 hours of APBL, 394 received ≤48 hours). E. coli
was the most common bloodstream isolate (56%), followed by
Klebsiella species (21%). The median time to CDI (interquartile range) was 11 (4–27) days. The overall incidence of CDI was
4.4% (95% CI, 2.8% to 6.0%), with significantly higher incidence
of CDI in patients who received >48 hours of APBL than in those
who received ≤48 hours of APBL. After adjustments for the propensity to receive >48 hours of APBL, end-stage renal disease and
receipt of >48 hours of APBL remained independently associated
with higher risk of CDI. This study showed that end-stage renal
disease and receipt of APBL for >48 hours are associated with
CDI in adults hospitalized for the treatment of Enterobacterales
BSI. Therefore, appropriate empiric antibiotic selection and early
de-escalation of APBL using clinical risk assessment tools or molecular RDT are likely to reduce the incidence of CDI in patients
with Enterobacterales BSI.
Impact of an Inpatient Antiretroviral Stewardship Team

Errors in antiretroviral (ARV) medication prescribing, particularly at transitions of care, remain a prevalent patient safety
issue, with reported rates as high as 86% [34]. DePuy and colleagues sought to determine if an ARV stewardship program
(ARVSP) composed primarily of an HIV pharmacist specialist

and ID physician would be able to identify and correct inpatient
ARV medication errors [17]. The team reviewed ARV orders
within 24 hours of admission and confirmed regimens with
outpatient HIV providers as needed. A standardized communication was entered within the electronic health record (EHR)
containing medication reconciliation notes and additional recommendations. A daily profile review was completed for all
patients throughout admission.
The overall 12-month error rate, medication error types, and
subsequent intervention acceptance rate were consistent with
other reports in the literature. However, there were several innovative ARVSP components to highlight in this study. This
was the first published report of cost avoidance associated with
an ARVSP. The interdisciplinary structure of the ARVSP was
unique and mimicked the established model for robust ASPs.
Daily profile review and standardized communication in the
EHR facilitated ongoing error monitoring, expanded capture
of intervention outcomes, and enhanced financial impact estimation. Additionally, this study identified novel risk factors for
ARV medication errors that can be applied to future ARVSP
development and research.
High- vs Low-Intensity Prospective Audit and Feedback

A major core ASP strategy supported by the IDSA and CDC
is prospective audit and feedback (PAF). While effective, PAF
is typically labor-intensive, difficult to implement in resourceand/or workforce-limited settings, and relies on provider acceptance of recommendations [31, 35]. The current literature
describes a wide variation in PAF designs that have attempted
to overcome these disadvantages.
Langford and colleagues examined the impact of a highintensity, twice-weekly interdisciplinary rounds-based PAF
compared with low-intensity (weekly review, 1-on-1 education)
PAF on antimicrobial use in internal medicine wards in a 400bed community hospital over a 4-year period [18]. A reduction
in the primary outcome of antimicrobial use was seen in the
high-intensity phase as compared with the low-intensity phase,
with a greater reduction in usage seen in the latter half of the
high-intensity period. No change was seen in clinical outcomes
of CDI, readmission rate, or mortality. The findings of this study
highlight the benefit of “handshake stewardship,” a term first
coined by Hurst and colleagues [36]. Although face-to-face
rounds have proven impactful on antimicrobial use, the time
requirements can be rate-limiting. Further studies are needed to
evaluate the impact of workload requirements associated with
high-intensity PAF to ensure appropriate return on investment
for the time-intensive approach.
Effects of Automatic Antibiotic Discontinuation

As described above, PAF is a fundamental strategy utilized by
ASP that engages providers after an antibiotic is prescribed [31].
Bolten and colleagues evaluated antibiotic usage comparing
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of CDI, recent NAAT results, administration of tube feeds,
laxatives, stool softeners, or contrast dye in the preceding 24
hours as well as imaging studies. Providers were contacted on
all NAATs that did not meet preauthorization criteria and recommended to cancel the test. Of note, patients in the stem cell
transplant unit were excluded.
The postintervention group had statistically significant improvement compared with the pre-intervention group with regards to the mean hospital-onset CDI (HO-CDI), incident rate
of HO-CDI, and standardized infection ratio. Interestingly, the
consumption of oral vancomycin did not differ between the 2
intervention periods. Overall, this study confirms that RDTs for
CDI must be used in conjunction with ASP to be an effective
patient care tool.

Telehealth-Based ASP in Community Hospitals

Community hospitals often have less access to ID expertise and
are less likely to have robust ASPs than academic medical centers [37]. Shively and colleagues sought to describe the practical
implementation and assess the effectiveness of a telehealthbased ASP (TeleASP) in 2 community hospitals using the expertise of a large health network in Pennsylvania [20]. On-site
hospitalists, advanced practice providers, and pharmacists
were trained by ID physicians and ID/ASP pharmacists from
within the large network. On-site providers were permitted to
order tier 1 antimicrobials for 24 hours, after which they could
be continued only with TeleASP or local ID approval. Tier 2
antimicrobials were not restricted but were monitored via PAF
during weekdays. There was no restriction or audit and feedback on nontiered antimicrobials unless they were encountered
by the TeleASP team in review of eligible patients. A review of
patients on broad-spectrum antimicrobials and those admitted
with select common infections was performed by remote ID
physicians who discussed patients by telephone with local pharmacists. Following the call, local pharmacists communicated
the interventions to primary teams. Antimicrobial use was collected for 12 months before TeleASP implementation and for
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6 months after implementation. The majority of recommendations made were accepted by the local clinicians. The most frequent type of intervention was de-escalation of antimicrobial
therapy. Tier 1 and tier 2 antimicrobial use decreased significantly during the intervention period compared with historical
control, while nontiered antimicrobial use increased. Local ID
consultations increased significantly during the intervention
period compared with historical control. The program led to
substantial cost-savings largely from an overall decrease in antimicrobial use. This study showed that a TeleASP in community
hospitals is likely to result in reduction in broad-spectrum antimicrobial use, increase in ID consultations, and reduction in
antimicrobial expenditures.
Core Antibiotic Stewardship Interventions in Community Hospitals

Antimicrobial stewardship guidelines recommend the implementation of preauthorization (PA) and/or PAF as the core
components of any ASP [31]. Anderson and colleagues sought
to determine the feasibility of implementing modified PA and
postprescription audit and review (PPR) in 4 community hospitals in North Carolina [21, 38]. The modified PA consisted of
a trained pharmacist reviewing all study antibiotic prescriptions
for approval during weekday study hours, and PPR consisted of
the stewardship team reviewing eligible prescriptions between
48 and 96 hours after order entry. Hospitals were paired based
on size, and 1 hospital from each pair was assigned to a modified
PA for 6 months, then transitioned to PPR for 6 months after a
1-month washout. The other 2 hospitals were assigned to PPR
for 6 months, then transitioned to modified PA for 6 months
after a 1-month washout. Antibiotics targeted were vancomycin, piperacillin-tazobactam, and the antipseudomonal
carbapenems on formulary. Antibiotic use was collected for
12 months before ASP implementation. An ID physician was
available for consultation at 2 participating hospitals. Eligible
patients were identified using lists generated from pharmacy
prescription databases. Implementing the 2 core stewardship
strategies was feasible, as evidenced by (1) approval of administration and committees at all study hospitals; (2) completion of pharmacist training; (3) initiation and implementation
of interventions; and (4) documentation of time required for
interventions. The majority of pharmacist recommendations
were accepted by clinicians. Study antibiotics were determined to be inappropriate 2 times more often during the PPR
period than during the PA period. Pharmacists recommended
a dose change more often in the PA period and de-escalation
more often in the PPR period. Antibiotic use did not decrease
during the PA period; however, it decreased significantly compared with matched historical control during the PPR period.
Length of hospitalization did not change throughout the study.
This trial showed that while strict PA is unlikely to be feasible
in community hospitals with limited resources, PPR can be an
effective stewardship strategy.
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traditional ASP PAF with an ASP-led automatic discontinuation of antibiotics policy (ADAP) in an 800-bed, tertiary care
academic teaching hospital [19]. The policy targeted duplicate
therapy, defined as unnecessary double anaerobic, atypical,
and/or β-lactam agents without documented rationale and excessive durations of therapy for prespecified disease states exceeding evidence-based recommendations. Antibiotics for >48
hours without a documented infection were also included in
the ADAP. Education on the ADAP scope was provided via the
pharmacy and therapeutics committee, and the ASP team documented ADAP interventions with written notes. An ID-trained
physician and ID-trained pharmacist comprised the ASP team.
The most common diagnoses encountered in the pre- and
post-ADAP groups were pneumonia, complicated cystitis, and
chronic obstructive pulmonary disease exacerbation. Excess
duration of therapy (73.5% vs 62.3%), followed by antibiotics
without an indication (18.5% vs 22.2%), was the most frequent reason for ASP intervention. The mean total number of
antibiotic days per patient and the percentage of patients discharged on antibiotics were reduced post-ADAP. There was a
nonsignificant increase in 30-day readmission after ADAP;
however, readmission rate due to an infectious diseases diagnosis was higher in the pre-ADAP group (65% vs 39%).
This single-center study demonstrated that an ASP-led
ADAP can reduce overall in- and outpatient antibiotic use
without increasing adverse patient outcomes. However, in
settings where ID-trained personnel are not readily available,
approval and implementation of this type of policy may be difficult to achieve.

Implementing Antimicrobial Stewardship in an Academic Dental Practice

Antimicrobial Stewardship in Patients With Cancer or Undergoing
Hematological Stem Cell Transplant

Antimicrobial stewardship in patients with hematologic malignancy is challenging, as the optimal approach is not well
defined. Implementation of stewardship interventions in this
patient population is prone to the same barriers of many ASPs
and thus should seek to find a balance between curtailing
overuse of broad-spectrum antimicrobial therapy while providing adequate therapy.
Webb and colleagues conducted a quasi-experimental preand postimplementation of 2 antimicrobial stewardship interventions in a hematological malignancy treatment unit [23].
The interventions consisted of monthly antibiotic cycling for
empiric treatment of febrile neutropenia and use of a clinical prediction rule to guide empiric vancomycin-resistant
Enterococcus faecium (VRE) therapy [42]. The primary outcome

for the antimicrobial cycling intervention was antipseudomonal
carbapenem consumption in days of therapy per 1000 patientdays. The primary outcome for the VRE therapy prediction score
intervention was days of daptomycin therapy per 1000 patientdays. Both outcomes were analyzed using an interrupted timeseries regression analysis. Secondary outcomes included VRE
colonization per 1000 admissions, inpatient mortality, and clinical infections due to VRE, ESBL-producing Enterobacterales,
phenotypically suspected AmpC-harboring Enterobacterales,
methicillin-resistant Staphylococcus aureus (MRSA), and CDI.
As outlined in Table 1, the interventions resulted in a significant decrease in carbapenem use and improved susceptibility in
Pseudomonas aeruginosa isolates postintervention. In turn, this
intervention likely also resulted in a decrease in daptomycin use
attributable to lower rates of VRE colonization and subsequent
VRE infections. The study also examined community ecology
data in order to determine if changes in infection rates pre- and
postimplementation were due to the antibiotic cycling intervention vs changes in local microbiology. The findings of this study
lend support to antibiotic cycling as it pertains to carbapenem
and daptomycin usage while not adversely impacting clinical
outcomes in the management of febrile neutropenic patients. It
is notable that the success of the program was facilitated by an
ASP pharmacist and close partnership with clinician leadership
to advance the stewardship initiatives.
Implementation of Electronic Stewardship Tools

Reporting to the National Healthcare Safety Network (NHSN)
Antimicrobial Use (AU) Option is specifically recommended
to facilitate AU benchmarking [5]. However, Graber and colleagues note NHSN report limitations in the areas of facility
matching, AU by infection diagnosis, and temporal assessment
of antimicrobial prescribing [24].
The authors attempted to overcome these limitations through
creation of AU visualization tools. The graphical displays were
built on a foundation of both disease state and time frame.
Pneumonia, urinary tract infection, and skin/soft tissue infection (PUS) were identified by ICD-9 and ICD-10 codes. Time
frame was described as choice, change, and completion (CCC),
representing the major AU decision points of empiric therapy,
de-escalation, and definitive course, respectively. Based on collaborative feedback from 1 physician and 1 pharmacist steward
at each of 8 Veterans Affairs (VA) facilities, the dashboards were
updated to include data on antimicrobial type and unit and to
allow for comparison across all or select VA sites. The stewards
implemented ASP initiatives at their respective facilities based
on needs identified by these individualized dashboards.
Reductions in total antimicrobial, anti-MRSA agent, and
antipseudomonal agent utilization were noted at intervention
facilities with statistically significant differences observed in
total and antipseudomonal agent use. Despite the resourceintensive requirements for dashboard development, these
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Dentists have become increasingly recognized as significant
prescribers of antimicrobial therapy. It is estimated up to 10%
of all outpatient antimicrobial prescriptions can be attributed
to dentists, with clindamycin being most frequently prescribed
[39]. However, best practices for antimicrobial stewardship in
the area of dentistry are lacking.
In conjunction with an academic dental practice, Gross and
colleagues sought to improve antimicrobial prescribing using
the CDC Core Elements of Outpatient Antibiotic Stewardship
[22, 40]. The University of Illinois at Chicago (UIC) College of
Dentistry provides care for >30 000 patients annually. In addition, dentists in Illinois account for nearly 80 antibiotic prescriptions per 1000 patients, thus illustrating an opportunity
for intervention [41]. Leadership from both the University of
Illinois Hospital and Health Sciences System ASP and the UIC
College of Dentistry met and ultimately made the development
of a dental ASP a strategic initiative. Baseline prescribing data
cross-referenced with patient visit and dental coding were reviewed, and potential areas for improvement were identified.
One particular area of concern was the number of prescriptions
for acute dentoalveolar conditions in the urgent care clinic. The
first practice intervention was to standardize antibiotic use for
dentoalveolar conditions given feasibility via educational intervention and subsequent impact. To support this intervention,
an evidence-based clinical decision support tool was developed
that provided drug selection and optimal duration of therapy.
While this represents a single intervention, the successful outcome as shown in Table 1 will facilitate expansion of the dental
ASP to other areas in the future.
This study provides a template for other programs to utilize
simple interventions to affect the prescribing of antimicrobials
in the dental setting. Moreover, this study also highlights the
effectiveness of collaboration between key stakeholders in different arenas as it pertains to stewardship.

results suggest that this type of tool would be effective for individualized, targeted ASP work across large health systems or
networks. Additionally, the novel CCC framework allows for a
unique drilldown on suboptimal antimicrobial prescribing at
precise points in the AU continuum. Overall, the dashboard
visualization approach allows for targeted selection of ASP
interventions from a robust data source across all ASP stages
regardless of previously implemented interventions.
DISCUSSION
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